MedTrace Logo

A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in Portugal

NCT07784387 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2026-08-28

No results posted yet for this study

Summary

The purpose of this study is to understand how the participants with high-risk non-muscle invasive bladder cancer are diagnosed, treated, and cared for in regular clinical practice in Portugal. HR-NMIBC is an early-stage bladder cancer that is limited to the inner lining of bladder but has a considerable high chance of cancer coming back or worsening.

Conditions

  • Urinary Bladder Neoplasms

Sponsors & Collaborators

  • Janssen-Cilag Farmaceutica Ltda.

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag Farmaceutica Ltda. Clinical Trial · Janssen-Cilag Farmaceutica Ltda.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-25
Primary Completion
2028-02-15
Completion
2028-02-25

Countries

  • Portugal

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07784387 on ClinicalTrials.gov